Kava for Generalised Anxiety

editor's picture

Editor ● 1 min read


A six-week, double-blind, randomised controlled trial involving chronic administration of kava (120mg kavalactones/day, titrated in non-response to 240mg kavalactones/day) or placebo for participants with generalised anxiety disorder.

Results showed no significant differences across groups for liver function tests, nor were there any significant adverse reactions that could be attributed to kava.

No differences in withdrawal or addiction were found between groups. Interestingly, kava significantly increased females’ sexual drive compared to placebo, with no negative effects seen in males. Further, it was found that there was a highly significant correlation between improved sexual function and performance, and anxiety reduction in the whole sample.


References

  1. Sarris J, Stough C, Teschke R,et al. Kava for the treatment of generalised anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res 2013;27(11):1723-1728. [Abstract]


DISCLAIMER: 

The information provided on FX Medicine is for educational and informational purposes only. The information provided on this site is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you have read here raises questions or concerns regarding your health.

Share / Print: 

SIGN UP TO OUR FREE eNEWS

editor's picture
Editor
This was brought to you by the FX Medicine editorial team.